This technology utilizes glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, to prevent and treat radiation-induced cardiac injury, offering a novel medical approach to protect the heart from damages caused by ionizing radiation.
Radiation-induced heart disease (RIHD) is a serious complication arising from exposure to ionizing radiation, particularly in cancer patients undergoing thoracic radiotherapy and individuals exposed in military or accidental radiation events. Current treatment options for RIHD are limited, with no approved medical countermeasures specifically addressing the prevention or mitigation of cardiac damage caused by radiation. The growing need for effective solutions to protect heart health in such contexts motivated research into potential therapeutic agents that could reduce inflammation, oxidative stress, and fibrosis associated with radiation exposure.
This innovation repurposes GLP-1 receptor agonists (GLP-1RAs)—a class of FDA-approved drugs originally designed to treat diabetes—as a novel solution to combat radiation-induced cardiac injury. GLP-1RAs, such as semaglutide, function by activating specific receptors that have beneficial effects beyond glucose regulation, including cardioprotective actions. In preclinical studies using irradiated mouse models, treatment with GLP-1RAs demonstrated significant reductions in cardiac inflammation, oxidative/nitrosative damage, fibrosis, improvements in post-irradiation survival and body weights as well as organ weights and in systolic and diastolic functions of the heart. The method supports both prophylactic administration before radiation exposure and therapeutic intervention after exposure, highlighting versatility in timing and application. The novelty lies in applying GLP-1 receptor modulation specifically for radiation-induced heart injury, a use not previously established in clinical practice. This approach offers a promising pathway for rapid clinical translation due to the existing regulatory approval of GLP-1RAs for other indications. By leveraging established pharmacological agents, the technology addresses a critical unmet medical need with potential for widespread adoption in multiple high-risk settings.
Photo for reference only, not a depiction of the invention.
• Repurposes an FDA-approved drug class, allowing faster clinical adoption and regulatory approval.
• Demonstrated efficacy in reducing inflammation, oxidative stress, fibrosis, and arrhythmias in preclinical models.
• Effective as both a preventive and post-exposure treatment for radiation-induced cardiac injury.
• Addresses a significant unmet need for medical countermeasures in clinical oncology, military, and civilian radiation exposure scenarios.
• Potentially reduces long-term cardiac complications, improving patient outcomes and quality of life.
• Protecting cancer patients undergoing thoracic radiotherapy from radiation-induced heart disease.
• Medical countermeasure for military personnel exposed to ionizing radiation during deployment.
• Emergency treatment for civilians exposed to radiation accidents or incidents.
• Potential adjunct therapy in combination with existing cardiac protective strategies in radiation oncology.
Patent pending.
This technology is at a TRL 4-5, supported by preclinical in vivo studies demonstrating the cardioprotective effects of GLP-1 receptor agonists in radiation-exposed animal models. Further clinical validation and regulatory development are needed to confirm efficacy and safety in humans and enable translation into clinical use.
This technology is available for licensing.